Lamictal XR Approved

1

Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.

 1 COMMENT

  1. Not to mention that GlaxoSmithKline markets Relenza (Zanamivir), effective against A H1N1 (previously known as swine flu) and which is almost as good as Roche’s Tamiflu. 😉

 LEAVE A REPLY

Please enter your comment!
Please enter your name here